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Abstract
Streptococcus pyogenes M/emm3 strains have been epidemiologically linked with enhanced infection severity and risk of
streptococcal toxic shock syndrome (STSS), a syndrome triggered by superantigenic stimulation of T cells. Comparison of S.
pyogenes strains causing STSS demonstrated that emm3 strains were surprisingly less mitogenic than other emm-types
(emm1, emm12, emm18, emm28, emm87, emm89) both in vitro and in vivo, indicating poor superantigenic activity. We
identified a 13 bp deletion in the superantigen smeZ gene of all emm3 strains tested. The deletion led to a premature stop
codon in smeZ, and was not present in other major emm-types tested. Expression of a functional non-M3-smeZ gene
successfully enhanced mitogenic activity in emm3 S. pyogenes and also restored mitogenic activity to emm1 and emm89 S.
pyogenes strains where the smeZ gene had been disrupted. In contrast, the M3-smeZ gene with the 13 bp deletion could
not enhance or restore mitogenicity in any of these S. pyogenes strains, confirming that M3-smeZ is non-functional
regardless of strain background. The mutation in M3-smeZ reduced the potential for M3 S. pyogenes to induce cytokines in
human tonsil, but not during invasive infection of superantigen-sensitive mice. Notwithstanding epidemiological
associations with STSS and disease severity, emm3 strains have inherently poor superantigenicity that is explained by a
conserved mutation in smeZ.
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Introduction
Streptococcus pyogenes is a major human pathogen, responsible
for a wide spectrum of clinical manifestations. These range from
non-invasive and self-limiting to severe, potentially lethal
invasive infections complicated by streptococcal toxic shock
syndrome (STSS). The development of STSS during S. pyogenes
invasive infection is hypothesized to result from exposure to
secreted streptococcal superantigens that leads to excessive
proliferation of T cells, accompanying cytokine release, inflam-
mation and tissue damage [1]. S. pyogenes can express several
different superantigens (reviewed in [2]) that can vary in their
potency, thus differences in mitogenicity within and between
M/emm-types can be influenced by the complement of
superantigen genes, as well as differences in expression or
degradation [3–6]. SMEZ is the most potent streptococcal
superantigen described, although produced in small amounts
compared to other superantigens, [7–10] and the smeZ gene is
present in the majority of S. pyogenes strains, with over 40
different alleles [8,11].
In the UK, which has the highest measured rate of invasive S.
pyogenes disease in Europe (3.33 per 100,000), infections with M/
emm3 type S. pyogenes are independently associated with a three-fold
increased risk of STSS, compared to patients infected with a
reference strain group (M/emm28) that is represented by large
numbers, and is associated with an average case fatality ratio [12].
Studies in the USA, Canada, and elsewhere in Europe have also
highlighted an increased risk of death associated with M/emm3 S.
pyogenes infection [13–16].
In this study, we compared superantigenicity of different S.
pyogenes emm-types, using mitogenicity as a surrogate measure, and
explored the hypothesis that superantigenic potency would be
associated with STSS. Surprisingly we observed that emm3 strains
had almost negligible mitogenicity compared to other emm-types.
We sought to determine whether this was due to a recently
identified 13 bp deletion within smeZ that yielded a premature stop
codon and predicted inactive protein expression [17]. We went on
to determine the frequency of the 13 bp deletion and the impact
on superantigenic function in emm3 strains.
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Results
Emm3 Isolates from STSS Patients Lack Mitogenic Activity
Compared with Other STSS Isolates, Both in vitro and in
vivo
The mitogenicity of a panel of 63 S. pyogenes isolates from cases
of confirmed STSS was evaluated in vitro using human mononu-
clear cells (MNC) (Figure 1A). Strains represented the most
common emm-types associated with STSS in the UK (emm1, n= 11;
emm3, n= 12; emm12 and emm87, n= 11; emm18, n= 5; emm28,
n = 7; emm89, n= 6). The complement of superantigens carried by
each isolate was determined by PCR (Table S1). Emm3 and emm1
strains were markedly less mitogenic than other emm-types
(Figure 1A) despite their reported association with STSS; this
was reproducible even when MNC from alternative donors were
used (not shown). In particular, some emm3 strains demonstrated
mitogenic activity that was barely above control levels, despite the
presence of 4 or 5 superantigen genes (speA, smeZ, speG, ssa, and
speK).
To determine whether emm3 S. pyogenes strains might change in
phenotype in vivo, during an infection, the superantigenic activity
of S. pyogenes strains of different emm-types was compared in vivo
using a murine intramuscular infection model; three representative
strains were tested for each of the seven STSS emm-types. In this
model, secreted bacterial superantigens enter the systemic
circulation, hence mouse serum acquires mitogenic properties
towards human lymphocytes [18]. Murine sera obtained 24 hours
after onset of infection were tested for mitogenic activity with
human MNC as a measure of released superantigen (Figure 1B).
Similar to the in vitro results, emm3 and emm1 strains released
markedly less mitogen into mouse serum than other emm-types,
with the exception of emm89 strains. These differences were not
attributable to differences in bacterial counts during infection;
despite producing the lowest mitogenic activity in mouse serum,
emm3, emm1 and emm89 strains demonstrated the greatest systemic
spread from the site of infection (thigh tissue) to the spleen and
liver (Table S2).
Emm3 Isolates Carry a Mutation in smeZ
Previously we had determined that five contemporary emm3 S.
pyogenes strains carried a smeZ gene containing a 13 bp deletion at
nucleotide position 316, that leads to a frame shift and a
premature stop codon predicted to truncate SMEZ [17]
(Figure 2). This smeZ allele (smeZ59N) was restricted to emm3
strains and was not detected in 44 other emm-types tested [17]. We
detected the 13 bp smeZ deletion mutation by PCR in all 12 emm3
S. pyogenes strains associated with STSS (strains listed in Table S1).
The same mutation was detected in 27/27 other emm3 S. pyogenes
invasive diseasestrains submitted to the reference laboratory that
included three of the most common MLST sequence types for
emm3 strains; ST15, ST315, and ST406 (http://spyogenes.mlst.
net/). The mutation was also identified in the two existing NCBI
sequences for M3 S. pyogenes originating from the USA (MGAS315,
GenBank accession number AE014074, [19]) and from Japan
(SSI-1, GenBank accession number BA000034, [20]).
Contribution of the 13 bp smeZ Mutation to Low
Mitogenicity of emm3 Strains
The mutation within the smeZ-M3 gene suggested that any
protein, if expressed, would be non-functional, thus potentially
accounting for the low mitogenic activity observed for emm3
strains. To confirm that the SMEZ-M3 protein is non-functional
and that the low mitogenic activity of emm3 isolates was not
accounted for by enzymatic degradation of SMEZ or interfer-
ence with T cell mitogenicity, an emm3 isolate, GAS-M3 (with
the smeZ-M3 gene) was transformed with a plasmid that
conferred over-expression of either a functional SMEZ protein
from an M89 strain (GAS-M3smeZ-M89) or the truncated SMEZ-
M3 protein (GAS-M3smeZ-M3). Supernatant from strain GAS-
M3smeZ-M89 increased proliferation of human MNCs by 3-fold
compared to the parental (untransformed) emm3 isolate, GAS-
M3 (Figure 3A), confirming that the M3 strain does not
produce an inhibitor that interferes substantially with mitogen
function. Supernatant from GAS-M3smeZ-M3 failed to enhance
proliferation, confirming that SMEZ-M3 is non-functional as a
mitogen. Transformation of GAS-M3 with the empty control
plasmid (GAS-M3control) did not affect proliferation of human
MNCs compared to untransformed GAS-M3 (not shown). Real
time PCR analysis demonstrated that the transformed isolates
expressed equivalent amounts of smeZ transcript from either
plasmid (GAS-M3smeZ-M89:163.0 copies of smeZ per 10,000
copies of proS and GAS-M3smeZ-M3:183.8 copies of smeZ per
10,000 copies of proS); therefore differences in expression could
not account for the differences in proliferation.
The 13 bp Deletion Abrogates Function of SMEZ in Other
Strain Backgrounds
To confirm that SMEZ-M3 cannot function as a mitogen in
other emm-types, we used genetically modified S. pyogenes strains
lacking functional smeZ and determined whether transformation
with plasmids encoding smeZ-M3 or smeZ-M89 could complement
the defect in mitogenicity. Disruption of smeZ in emm1 S. pyogenes
(GAS-M1DsmeZ) led to a ,40% reduction in proliferation
(Figure 3B); this strain also has genes encoding for other
superantigens (speA, speG, speJ). A more dramatic reduction in
mitogenicity (,80%) was observed after disruption of smeZ in an
emm89 strain (GAS-M89DsmeZ) (Figure 3C), despite the presence
of genes encoding for other superantigens (speG, speH, speJ)
consistent with an earlier report [9]. Mitogenic activity was fully
restored when GAS-M1DsmeZ and GAS-M89DsmeZ were trans-
formed to over-express functional SMEZ-M89. Transformation of
GAS-M1DsmeZ (Figure 3B) and GAS-M89DsmeZ (Figure 3C) to
over-express the M3 form of SMEZ, however, failed to restore
mitogenic potential, again confirming that SMEZ-M3 is not a
functional mitogen.
The 13 bp smeZ-M3 Deletion Reduces the Potential of
emm3 S. pyogenes to Stimulatecytokine Production in
Human Tonsil Cells
Acute inflammation mediated by smeZ expression may be
important for tonsillopharyngeal colonization of GAS [21]. To
determine if the 13 bp mutation in smeZ-M3 might affect
inflammation in tonsil, human tonsil cells were cultured with
bacterial cell-free supernatants from GAS-M3control, GAS-M3smeZ-
M89 or GAS-M3smeZ-M3. After two and five days of culture,
production of TNFa, TNFb, IFNc, IL-10, IL-17, IL -5, and IL-12
were measured in supernatant, focusing on cytokines that have
previously been identified as important in the human response to
superantigens (Figure 4). In comparison to GAS-M3smeZ-M3,
expression of functional SMEZ by GAS-M3smeZ-M89 enhanced
the production of the modulating cytokine IL-10 at both times
points, and also increased production of TNFa on day 2 and
TNFb and IL-17 on day 5 consistent with an effect on T cells.
There was also a non-significant increase in IFNc production by
GAS-M3smeZ-M89. The levels of each cytokine induced by
expression of functional SMEZ were comparable to those induced
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by GAS-M1control, which naturally expresses a functional SMEZ
(Figure 4). In contrast, expression of SMEZ-M3 by GAS-M3smeZ-
M3 did not affect cytokine production at any time point.
Production of IL-5 and IL-12 were below the limit of detection.
Experiments were repeated using a second tonsil donor with
similar results (not shown).
The 13 bp Deletion in smeZ-M3 Limits Only Interleukin-5
Production during Invasive Infection of Superantigen-
sensitive Mice
To determine whether the non-functioning SMEZ-M3 affects
cytokine production in vivo during GAS-M3 infection, we infected
superantigen-sensitive HLA-DQ8 transgenic mice with GAS-
M3smeZ-M3 or GAS-M3smeZ-M89 with a low intramuscular inoculum
and measured both tissue and serum levels of cytokines after 24 h
using a bead array.
In contrast to ex-vivo stimulation of human tonsil cells and in
contrast to previous studies using GAS-M89 [9], expression of
functional SMEZ during intramuscular infection of HLA-DQ8
transgenic mice did not increase local tissue levels of TNFa, IL-10,
IL-17 or IFNc. In fact, mice infected with GAS that expressed the
non-functional smeZ gene (M3smeZ-M3) had a trend for higher tissue
cytokine levels (IL-17, IL-10, IL-1b) compared with mice infected
with GAS expressing the functional smeZ gene (M3smeZ-M89)
(Figure 5A). Most tissue cytokines were unaffected by the 13 bp
deletion in SMEZ however (Figure S1).
The only cytokine influenced by the 13 bp deletion in smeZ was
IL-5; IL-5 was higher in GAS-M3smeZ-M89 infection, not only at the
Figure 1. Emm3 STSS isolates show emm-type specific differences in overall mitogenicity. A.Human MNC proliferation response to culture
supernatants from 63 Streptococcus pyogenes streptococcal toxic shock syndrome (STSS) isolates grouped by emm-type (numbers per group: emm1,
n = 11; emm3, n = 12; emm12 and emm87, n = 11; emm18, n = 5; emm28, n = 7; emm89, n = 6). Negative; tissue culture media (RMPI) alone. Outliers are
represented as individual circles. Representative of 2 experiments performed on different donors. B. Human MNC proliferation response to sera
obtained from CD1 mice 24 hours after being infected with one of three S. pyogenes strains representing each emm-type; two mice were infected per
strain. Negative; uninfected mouse serum. Proliferative response is measured as counts per minute (cpm) of tritiated-thymidine uptake. Median and
5th, 25th, 50th, 75th, and 95th centiles shown.
doi:10.1371/journal.pone.0046376.g001
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site of infection but also in the serum (Figure 5A and B). Serum
levels of other cytokines were no different between the two infected
mouse groups (Figure S2).
To ensure that the two bacterial strains used had exhibited the
expected phenotype in vivo, we assessed the mitogenic activity
present in the thigh tissue and serum 24 h after infection. As
expected, GAS-M3smeZ-M3 resulted in markedly lower mitogenic
activity both at the local site of infection (thigh tissue homogenate,
Figure 5C) and in the serum (Figure 5D) compared with GAS-
M3smeZ-M89. The differences observed in mitogenicity and cytokine
response were not due to measurable differences in bacterial
burden as both groups had a similar bacterial load in thigh tissue
after 24 hrs infection (GAS-M3smeZ-M3, median; 2610
5 CFU/mg
range; 16105–36105 CFU/mg and GAS-M3smeZ-M89, median;
16105 CFU/mg, range; 56104–56105 CFU/mg) and neither
group demonstrated systemic spread.
Discussion
Invasive infections due to emm3 S. pyogenes are widely associated
with increased disease severity and, in the UK, with risk of STSS
compared with other emm-types [12–15]. Intriguingly, emm3 S.
pyogenes strains demonstrated very low mitogenic activity compared
with other dominant emm-types that cause STSS; indeed, some
emm3 strains had little mitogenic activity above background, which
was surprising given the complement of 4–5 superantigen genes
including speA. The observed deficiency in mitogenicity did not
change even when measured in vivo, a setting where expression of
superantigens can be enhanced. Emm3 strains carry a 13 bp
deletion mutation in the smeZ sequence that changes the reading
frame, resulting in a premature stop codon that is predicted to
preclude expression of a functional protein [17,22]. Thus, despite
the presence of the smeZ gene, emm3 strains have no ability to
produce active SMEZ superantigen. To a large extent this explains
the failure of emm3 strains to match the mitogenic activity of other
strains. The aberrant M3-smeZ was unable to restore mitogenicity
when over-expressed in an emm3 strain, and also could not
function when transferred to alternative S. pyogenes emm-types (emm1
and emm89). Strong mitogenic activity was associated with a
functional smeZ gene and major reductions in mitogenic activity
were associated with a non-functioning smeZ gene.
There are over 40 different smeZ alleles across the different emm-
types sharing high pair-wise identity (94–99%) [8,11], however the
region surrounding the 13 bp deletion that occurs in the emm3
smeZ allele (smez-59N) is actually highly divergent across all the
different alleles from different emm-types. Although no other non-
emm3 alleles demonstrated deletions within this region, three smeZ
alleles, smez-6, smez-19 and smez-23 from different emm-types had
frame-shift single base pair deletions that occur closer to the N-
terminus [8]. The 13 bp deletion in smeZ was found in all 39 emm3
GAS strains tested, including strains from three different multi-
locus sequence types (ST15, ST315 and ST406). Further to this,
the 13 bp deletion has also been found in all of 200 UK emm3
strains of ST15, ST315 or ST406, recently sequenced (unpub-
lished). The deletion in smeZ was also present in emm3 genome
strains from Japan (SSI-1, GenBank accession number BA000034)
[20] and the USA (MGAS315, GenBank accession number
AE014074) [19], both ST15. We were also able to identify the
deletion in the Canadian emm3 strains, sequenced by Beres et al
[23], by mapping the reads available on the short read archive
(Project SRP000775) to the smeZ locus from the M1 strain
MGAS5005. However, PCR analysis would be required to
confirm that the deletion was identical to that found in UK
Figure 2. emm3 isolates have a 13 base pair (bp) deletion within the smeZ locus. Representation of the smeZ locus from emm1 (M1) and
emm3 (M3) strains. Nucleotides 1 to 3 encode the start codon (shown in bold). From 73 bp of the nucleotide sequence, the amino acid sequence of
the mature SMEZ protein is shown. Emm3 strains have a 13 bp deletion at 316 bp (highlighted by a shaded box) that results in a frameshift and a
predicted premature stop codon after 86 amino acids (shown as *). The forward primer and the reverse primer amplify the full length smeZ locus. The
13 bp deletion was detected using a forward (truncated) primer that anneals specifically to the region containing the deletion.
doi:10.1371/journal.pone.0046376.g002
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Figure 3. emm3 strains have low mitogenicity due to the mutation in smeZ. A. MNC proliferative response to culture supernatants from an
emm3 isolate, GAS-M3 carrying the typical M3-smeZ with 13 bp deletion, GAS-M3 over-expressing the functional M89 form of SMEZ (GAS-M3smeZ-M89)
and GAS-M3 over-expressing the M3-SMEZ (GAS-M3smeZ-M3). B. Experimental smeZ mutation in emm1 S. pyogenes (GAS-M1) reduced MNC
proliferation (GAS-M1DsmeZ). Proliferative response was restored when GAS-M1DsmeZ over-expressed the functional M89 form of SMEZ (GAS-
M1smeZ-M89) but not with M3-type form of SMEZ (GAS-M1smeZ-M3). C. A similar result was obtained using an emm89 strain (GAS-M89) with an
experimental mutation in smeZ (GAS-M89DsmeZ). Proliferation was restored when GAS-M89DsmeZ over-expressed the functional M89 form of SMEZ
(GAS-M89smeZ-M89) but not with M3-type form of SMEZ (GAS-M89smeZ-M3). Negative; media alone.Proliferation was measured as counts per minute
Non-Functional smeZ in emm3 S. pyogenes Strains
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emm3 as the region of divergence downstream of the deletion
introduced ambiguity in the read mapping. Furthermore, the emm3
smeZ deletion is not a very recent event since we detected the same
13 bp deletion in a 1931 emm3 S. pyogenes puerperal sepsis isolate
from Queen Charlottes Hospital, Hammersmith (Lynskey N. et al,
unpublished). We postulate that the smeZ deletion is likely to have
arisen early in the evolution of the emm3 lineage and the
pseudogene conserved over decades.
Although smeZ-M3 encodes a mutated gene that lacks classical
T cell mitogenic function, it remains possible that the truncated
SMEZ-M3 has an alternative as-yet unrecognized function in
GAS-M3 strains, such as, for example, interfering with the
function of other superantigens or acting as a non-mitogenic
activator of class II-positive cells. Results showed that smez-M3 is
transcribed at a similar level to functional smeZ-M89 although we
are unable to confirm if truncated SMEZ-M3 polypeptide is
actually produced.
Interestingly, emm1 strains were also poorly mitogenic compared
with other emm-types, both in vitro and in vivo. This was surprising
since emm1 strains all carried speA, speG, and speJ as well as an
intact smeZ gene. SPEA production is known to account for only a
small proportion of emm1 mitogenic activity in vitro [24], although
emm1 strains are able to upregulate production of superantigen
during deep tissue infection in vivo [25,26]. SPEJ is a superantigen
that selectively expands T cells bearing the Vb2 receptor [27];
since this is one of the largest subfamilies of human T cells, it was
expected that emm1 strains might demonstrate heightened
mitogenic activity compared with other emm-types. Nonetheless,
targeted mutation of smeZ demonstrated clearly that SMEZ is an
important component of emm1 mitogenic activity, similar to effects
previously observed in an emm89 S. pyogenes strain [9]. We cannot
exclude the possibility that emm1 and emm3 strains secrete proteins
that are toxic to human T cells, although the ability of smeZ-M89
to confer mitogenicity suggests such an effect is not major.
Degradation of superantigens by the streptococcal cysteine
protease, SPEB may also contribute to reduced mitogenic activity
of S. pyogenes [6] while the enhanced mitogenic properties of other
emm-types may relate to synergistic actions of combinations of
superantigens.
In addition to inducing T cell-derived cytokines, superantigens
such as SMEZ can enhance TLR expression and signaling [9,28]).
The 13 bp deletion in smeZ limited pro-inflammatory cytokine
production induced by GAS-M3 in tonsil cell suspension. We
speculate that this could be of benefit to GAS-M3 as it may limit
local inflammation in the pharynx, perhaps delaying the onset of
symptoms and the innate or adaptive immune response to
infection.
In contrast, the 13 bp deletion in smeZ did not appear to have
marked effects on cytokine production elicited by GAS-M3 during
in vivo invasive infection, with the exception of IL-5. Indeed the
induction of IL-5 appeared to be largely dependent on SMEZ.
Superantigen-induced expression of IL-5 in vitro has been
previously reported [7,29]. IL-5 is an eosinophilopoietic cytokine
able to promote eosinophil maturation and survival; when
activated, eosinophils can directly kill and enhance clearance of
bacteria [30,31]), thus a reduction in IL-5 may be of benefit to M3
GAS.
It was intriguing that the 13 bp deletion in smeZ did not have a
wider impact on cytokines during invasive infection with GAS-M3
and, in certain cases, appeared to result in higher levels of cytokine
despite very low levels of mitogenic activity in serum. This
indicates that GAS-M3 has potent mechanisms of inducing
cytokines during infection that are distinct from superantigen
production, although we cannot exclude the additional possibility
that a truncated form of SMEZ-M3 may play a role in enhancing
inflammation. Emm3 S. pyogenes were recently shown to have
acquired a novel prophage conferring the ability to produce a
secreted phospholipase A2 which may play a role in lethal sepsis
[32]. Clinical criteria that fulfill a diagnosis of septic shock due to
S. pyogenes will normally also fulfill criteria required for STSS.
Coupled with the many other virulence factors released by S.
pyogenes, it is likely that STSS associated with emm3 S. pyogenes
infection may not always require superantigen production.
Materials and Methods
Bacterial Strains
63 S. pyogenes isolates from patients with STSS meeting the
criteria defined by the Working Group on Severe Streptococcal
Infections [33], were provided by the Streptococcal Reference
Laboratory, Health Protection Agency (HPA, London, UK), and
represented emm-types that had been associated with STSS in at
least five patients. These included 54 isolates from 2003–2004
(from a total of 167 STSS cases identified in England and Wales)
and an additional 9 isolates from 2005–2006. Emm-typing was
performed as previously reported [34]. Emm3 isolates from patients
with confirmed invasive S. pyogenes infection without STSS were
also provided by the HPA.
PCR Analysis
The 13 bp deletion at position 316 of the smeZ nucleotide
sequence of emm3 S. pyogenes strains is depicted in Figure 2. PCR
primers were designed to amplify and distinguish the mutated smeZ
gene, with the 13 bp deletion, from the non-mutated from, using a
universal forward smeZ primer, Z1 (CTCCTGAAAAGAGGC-
TATTTATG), a universal reverse smeZ primer, Z2 (CATACT-
TACTTTTTAGAGGATTC), and an additional forward primer
designed to anneal to the mutated (deleted) region, Z3 (AAC-
TACTTGTCAGAAGGAATAC). Non-mutated smeZ yielded an
amplification product of 796 bp with primers Z1 and Z2, while the
mutated smeZ yielded a product of 474 bp with primers Z3 and
Z2. Genotyping for other toxin genes was undertaken by multiplex
polymerase chain reaction using the method previously reported
[35] but analyzed by agarose gel electrophoresis. Primers that
amplify the entire smeZ and speJ genes were additionally used, as
allelic variation or pseudogenes can yield false negative and false
positive results [36] (smeZ-F 59-TAAAGGCTTTTTTGCT
TGTTTCA, smeZ-R 59-TTAGGAGTCAATTTCTATATC-
TAAATGCCC; speJ-F 59-GATAGTGAAAATATTA, speJ-R 59-
TTATTTAGTCCAAAGG).
Mitogenicity Assay
Total mitogenic activity of cell-free S. pyogenes supernatants was
measured using a standard 72 hour human blood mononuclear
cell (MNC) proliferation assay, as previously described [9]. Isolates
were grown at 37uC to stationary phase in antibiotic-free tissue
culture medium (RPMI 1640, Invitrogen, UK) containing fetal calf
serum and L-glutamine [9], and bacterial cells were removed by
(cpm) of tritiated-thymidine uptake and the percentage proliferation for each strain was calculated relative to the wild type strain (GAS-M3, GAS-M1,
GAS-M89 respectively). Data are mean (+standard deviation) of three measurements. Representative of two experiments performed using different
donor MNC.
doi:10.1371/journal.pone.0046376.g003
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Figure 4. Functional SMEZ is required to stimulate production of cytokines from human tonsil cells. Human tonsil cell suspensions were
cultured with bacterial cell-free culture supernatants from GAS-M3control(white bars), GAS-M3smeZ-M89 (black bars) and GAS-M3smeZ-M3 (gray bars). After
2 and 5 days incubation cell-free media were obtained from cultures and production of TNFa, TNFb, IL-10, IL-17 and IFNc were measured by ELISA.
Horizontal dotted lines represent the mean level of cytokines produced after co-culture with bacterial cell-free culture supernatants from GAS-
M1control on day 2 and day 5. Mean (+ standard deviation) of three replicates measured in duplicate. Representative of two experiments performed on
different donors. Statistical analysis was performed using ANOVA with Bonferroni multiple comparison.
doi:10.1371/journal.pone.0046376.g004
Non-Functional smeZ in emm3 S. pyogenes Strains
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centrifugation and 0.2 mM filtration. There were no significant
differences in growth between emm-types. Proliferation of human
MNCs was measured by tritiated-thymidine uptake after 72 hour
co-incubation with 1:100 dilution of cell-free, filter-sterilized
bacterial supernatant in the absence of human serum as previously
described [9]. Human MNCs were obtained from at least two
Figure 5. Functional SMEZ is not required for production of inflammatory cytokines in superantigen-sensitive mice. Groups of five
superantigen-sensitive HLA-DQ8 female mice were infected for 24 hours intramuscularly (thigh) with 86107 CFU emm3 S. pyogenes strains; GAS-
M3smeZ-M89 and GAS-M3smeZ-M3.A. Thigh tissue homogenate from mice infected with GAS-M3smeZ-M3, over-expressing SMEZ-M3 demonstrated
significantly higher levels of IL-17 and IL-1b compared to GAS-M3smeZ-M89 infected thigh homogenate. Tissue from GAS-M3smeZ-M3 infection also
demonstrated non-significant increases in IL-10 (p= 0.059), IL-1a (p= 0.095) and IL-6 (p= 0.15). In contrast, GAS-M3smeZ-M89 had higher levels of IL-5
(p=0.056). TNFa and IFNc were similar in both groups. B. Mice infected with GAS-M3smeZ-M89 also had significantly higher levels of IL-5 in the
circulating serum compared to GAS-M3smeZ-M3 infected mice. Horizontal dotted lines; lowest detectable level of each cytokine. Mitogenic activity was
also measured in the thigh tissue homogenate (C) and serum (D) using human MNCs. GAS-M3smeZ-M89 demonstrated consistently higher mitogenic
activity due to the over-expression of functional SMEZ compared to GAS-M3smeZ-M3. Horizontal dotted lines; proliferation level of uninfected control
mouse thigh homogenate (C) or serum (D). Median and 5th, 25th, 50th, 75th, and 95th centiles are shown. For analysis, samples with unmeasurable
levels of cytokine were assigned a value half the lowest detectable value. Proliferation was measured as counts per minute (cpm) of tritiated-
thymidine uptake. Statistical analysis was performed using Mann-Whitney.
doi:10.1371/journal.pone.0046376.g005
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different healthy donors. In addition to bacterial supernatant, the
mitogenic activity of murine sera and thigh tissue homogenate
were also tested at a 1:100 dilution and co-incubated with human
MNCs for 72 hours.
Genetic Manipulation of emm1, emm3 and emm89 S.
pyogenes Isolates
To determine whether mitogenic activity could be restored to
an emm3 S. pyogenes strain (GAS-M3) with a functional copy of smeZ,
the strain was transformed with the shuttle plasmid pDL278
carrying a copy of a functional smeZ gene from an emm89 strain
with native promoter (pDLsmeZ-M89) to generate strain GAS-
M3smeZ-M89, using methods described previously [37]). As a
control, GAS-M3 was also transformed with pDL278 carrying a
copy of the smeZ locus with native promoter from emm3 S. pyogenes
that contains the 13 bp deletion and premature stop codon
(pDLsmeZ-M3), to generate strain GAS-M3smeZ-M3. GAS-M3 also
has genes for superantigens speA, speG, speK and ssa. To assess
whether smeZ-M3 could function in an alternative emm-type S.
pyogenes strain, the smeZ gene was firstly disrupted in emm1 S.
pyogenes (GAS-M1) using methods described previously [9] to
generate GAS-M1DsmeZ. GAS-M1DsmeZ was then transformed
with either pDLsmeZ-WT or pDLsmeZ-M3. Additionally, these
two plasmids were also used to transform a previously described
emm89 strain (GAS-M89) with a disrupted smeZ gene (GAS-
M89DsmeZ) [9]. Where additional control strains were needed,
parental GAS-M3, GAS-M1 and GAS-M89 strains were also
transformed with the empty shuttle plasmid pDL278 to give GAS-
M3control, GAS-M1control and GAS-M89control. Strains are listed in
Table 1.
Real Time PCR Analysis
S. pyogenes cells were obtained following supernatant collection
for mitogenicity assay. RNA was extracted and real time PCR was
performed as previously described [38] using SYBR Green
Jumpstart Taq Readymix (Sigma-Aldrich, UK). Primers Z4 59-
TCCCTTCTAAGGAATATCTATAGTACGATTG and Z5 59-
TTCCAATCAAATGGGACGG were designed to amplify a
209 bp target region of smeZ common to all known alleles. The
housekeeping gene proS was also amplified alongside smeZ, using
primers proS-F 59-TGAGTTTATTATGAAAGACGGCTA-
TAGTTTC and proS-R 59-AATAGCTTCGTAAGCTTGAC-
GATAATC to generate a 93 bp product [39]. Copies of smeZ and
proS transcripts were calculated against a standard plasmid
containing the target region of the smeZ gene and the proS gene.
Copies of smeZ transcript were then normalized against copies of
proS transcript.
Tonsil Cell Stimulation
Human tonsils were collected from adults undergoing routine
tonsillectomy by the Imperial College Healthcare Trust Tissue
Bank. Healthy tissue was cut into small sections which were then
filtered through a 70 mM cell sieve with tonsil media (RPMI 1640,
10% fetal calf serum, 100 mM L-Glutamine, 250 iu/ml Penicillin,
250 mg/ml Streptomycin, 100 mg/ml Kanamycin, 2.5 mg/ml
Amphotericin B; Invitrogen, UK) (method adapted from [40]).
Cells were then washed twice before resuspending to 26106 cells
per ml in tonsil media. In a 48 well plate format 1 ml of cells were
incubated with 10% bacterial culture supernatant as for mitoge-
nicity assays. After 48 hours (day 2) of media 500 ml was removed
and stored at 220uC for cytokine analysis, and replaced with
500 ml fresh tonsil media. Cells were further cultured until day 5
when cells were removed by centrifugation and supernatant was
stored at 220uC.
Bacterial Infection
Female outbred CD1 mice were infected intramuscularly (thigh)
with 106–107 CFU of S. pyogenes; three strains were used from each
STSS-associated emm-type (emm1, 3, 12, 18, 28, 87 and 89) and two
mice were infected per strain. After 24 hours of infection, mice
were euthanized and blood was taken by cardiac puncture for
CFU quantification and serum. Spleen, liver and infected thigh
muscle were excised, individually weighed and homogenized in
sterile PBS before plating on Columbia horse blood agar to
quantify viable CFU. Remaining blood was centrifuged and serum
was collected and stored at 220uC for testing mitogenic activity.
Female humanized transgenic C57/BL/10HLA-DQ8 mice (kind-
ly supplied by Daniel Altmann, Imperial College) were used as
they are sensitive to superantigens including SMEZ [9]. Groups of
5 mice were infected intramuscularly (thigh) with 86107 CFU
Table 1. S. pyogenes strains used in this study.
Strain Genotype
GAS-M1 emm1 strain (H305), wild type for smeZ
GAS-M1DsmeZ smeZ gene disruption in GAS-M1
GAS-M1DsmeZsmeZ-M89 GAS-M1DsmeZ over-expressing functional SMEZ from GAS-M89
GAS-M1DsmeZsmeZ-M3 GAS-M1DsmeZ over-expressing M3-type SMEZ (which contains a 13 bp deletion)
GAS-M1control GAS-M1 transformed with empty shuttle plasmid
GAS-M89 emm89 strain (H293), functional smeZ (smeZ-13 allele)
GAS-M89DsmeZ smeZ gene disruption in GAS-M89 strain (H377)
GAS-M89DsmeZsmeZ-M89 GAS-M89DsmeZ over-expressing functional SMEZ from GAS-M89
GAS-M89DsmeZsmeZ-M3 GAS-M89DsmeZ over-expressing M3-type SMEZ (which contains 13 bp deletion)
GAS-M89control GAS-M89 transformed with empty shuttle plasmid
GAS-M3 emm3 strain with M3-smeZ (which contains a 13 bp deletion) (H471)
GAS-M3smeZ-M89 GAS-M3 over-expressing functional SMEZ from GAS-M89
GAS-M3smeZ-M3 GAS-M3 over-expressing M3-type SMEZ which contains a 13 bp deletion)
GAS-M3control GAS-M3 transformed with empty shuttle plasmid
doi:10.1371/journal.pone.0046376.t001
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emm3 S. pyogenes strains; GAS-M3smeZ-M89 and GAS-M3smeZ-
M3.After 24 hours, mice were euthanized and organs excised
and plated as above. Both serum and infected thigh tissue
homogenate were collected and stored for testing mitogenic
activity and cytokine analysis using LuminexH (Invitrogen).
Cytokine and Chemokine Measurement
TNFa, TNFb, IFNc, IL-10, IL-12,IL-17 (all R&D, UK), IL-5
(Peprotech, UK) and MCP-1 (Peprotech) were measured in
human tonsil cell culture media using enzyme-linked immunosor-
bent assay (ELISA). Murine cytokine and chemokines were
measured in infected serum or thigh homogenate using a mouse
cytokine LuminexH 20-plex panel (Invitrogen) and analyzed on a
Bio-Rad Bio-Plex 200 system. The cytokines and chemokines
measured were as follows; TNFa,GMCSF, FGF, VEGF, IL-1a,
IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, MIP-1a,
MCP-1, IFNc, IP-10, MIG, and KC. For analysis, samples below
the lowest level of detected were assigned a value half of the lowest
measurable value.
Ethics
The use of anonymized human tonsil tissue for research
purposes was conducted within the remit of the Imperial HTA
licence covering hospitals within ICHT and patients gave
informed consent to use of tissues that would otherwise be
discarded. Mice were used in accordance with UK Home Office
guidance and subject to protocols set out in PPL 70/7379
approved by the Imperial College Ethical Review Process (ERP)
panel.
Statistical Analysis
All statistics were performed using non-parametric analysis with
GraphPad Prism version 5.0 for Windows, GraphPad Software,
San Diego California USA. *; p,0.05.
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Figure S1 Cytokine levels in thigh tissue homogenate
from superantigen-sensitive HLA-DQ8 mice infected
with GAS-M3smeZ-M89 (White box-whisker) or GAS-
M3smeZ-M3 (Grey box-whisker). Five mice per group were
infected intramuscularly and after 24 hours infected tissue was
removed and homogenated in sterile PBS. Cytokines were
measured using LuminexH. Dotted horizontal line; lowest
detectable level of each cytokine. For analysis, samples with
undetectable levels of cytokine were assigned a value half the
lowest detectable value.
(TIF)
Figure S2 Cytokine levels in serum from superantigen-
sensitive DQ8mice infected with GAS-M3smeZ-M89 (White
box-whisker) or GAS-M3smeZ-M3 (Grey box-whisker). Five
mice per group were infected intramuscularly and after 24 hours
blood was removed by cardiac puncture. Cytokines were
measured using LuminexH. Dotted horizontal line; lowest
detectable level of each cytokine. For analysis, samples with
undetectable levels of cytokine were assigned a value half the
lowest detectable value.
(TIF)
Table S1 Superantigen profile of each STSS isolate
determined by PCR.
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Table S2 Bacterial colony forming units in spleen and
liver following intramuscular infection with 7 different
emm-types of S. pyogenes.
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